Related Experiment Video

Updated: Feb 16, 2026

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

7.9K

Protein kinase D2: a versatile player in cancer biology

Ninel Azoitei1, Mathias Cobbaut2, Alexander Becher3

  • 1Center for Internal Medicine I, University of Ulm, Ulm, Germany. ninel.azoitei@uni-ulm.de.

Oncogene
|December 21, 2017
PubMed

Insights

Protein kinase D2 (PKD2) is a key regulator in cancer progression, driving hallmarks like growth and metastasis. This review explores PKD2

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • Protein kinase D2 (PKD2) is a serine/threonine kinase within the calcium-calmodulin kinase family.
  • PKD2 is activated by growth factors, phorbol esters, and G-protein-coupled receptor agonists.
  • PKD2 is implicated in cancer hallmarks such as uncontrolled growth, survival, neovascularization, metastasis, and invasion across numerous cancer types.

Purpose of the Study:

  • To review the multifaceted roles of PKD2 in cancer, analyzed through the lens of established cancer hallmarks.
  • To present the current understanding of PKD2 status, affected signaling pathways, and molecular mechanisms in tumorigenesis and progression.
  • To discuss emerging small-molecule inhibitors targeting PKD/PKD2 and the ongoing need for novel chemotherapies.

Main Methods:

  • Literature review synthesizing existing research on Protein kinase D2 (PKD2) function in various cancers.
  • Analysis of PKD2's role in relation to the cancer hallmarks defined by Hanahan and Weinberg.
  • Examination of molecular mechanisms, signaling pathways, and therapeutic strategies involving PKD2.

Main Results:

  • PKD2 contributes significantly to multiple cancer hallmarks, including proliferation, survival, angiogenesis, and metastasis.
  • Dysregulation of PKD2 and its associated signaling pathways are common in diverse malignancies.
  • Small-molecule inhibitors targeting PKD/PKD2 show promise, but further therapeutic development is necessary.

Conclusions:

  • PKD2 is a critical mediator of tumorigenesis and cancer progression, making it a potential therapeutic target.
  • Understanding PKD2's molecular mechanisms is crucial for developing effective anti-cancer strategies.
  • Continued research into PKD2 inhibitors and combination therapies is essential for improving cancer treatment outcomes.

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.5K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.7K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
8.7K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.1K